Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
Background: Several studies have assessed the efficacy of re-induction and subcutaneous intensification of ustekinumab (UST) to regain clinical remission of inflammatory bowel disease (IBD). However, very few have evaluated the effectiveness of intravenous UST for this purpose.Objectives: The aims o...
| Autores: | , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| Repositorio: | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| OAI Identifier: | oai:i3pt.fundanetsuite.com:p6553 |
| Acceso en línea: | https://i3pt.portalinvestigacion.com/publicaciones/6553 |
| Access Level: | acceso abierto |
| Palabra clave: | Crohn's disease inflammatory bowel disease ustekinumab |
| Sumario: | Background: Several studies have assessed the efficacy of re-induction and subcutaneous intensification of ustekinumab (UST) to regain clinical remission of inflammatory bowel disease (IBD). However, very few have evaluated the effectiveness of intravenous UST for this purpose.Objectives: The aims of the study were to evaluate the efficacy of high-dose intravenous UST (USTiv) for regaining remission in Crohn's Disease (CD) and to assess the safety of the drug.Design: Observational, retrospective, single-center study.Methods: All patients who had received intravenous UST to regain remission until June 2023 were included. Clinical response was evaluated using the Harvey-Bradshaw Index. Drug survival was calculated using Kaplan-Meier curves.Results: Twenty-three patients (52% female, mean age 40.5 +/- 13.9) with CD were included. Seven (30%) patients had an incomplete primary response to UST, while 16 (70%) presented a secondary loss of response. Clinical response rates for USTiv administered monthly were 17/23 (73.9%) at week 8, 14/23 (60.9%) at week 16, and 10/12 (83.3%) at 1 year. Clinical remission rates were 11/23 (47.8%), 9/23 (39.1%), and 8/12 (66.7%), respectively. Median drug survival was 15.3 +/- 7.7 months. Two patients (8%) experienced recurrent mild respiratory infections. No patients discontinued USTiv due to adverse events.Conclusion: More than half of the patients with CD who underwent maintenance treatment with USTiv regained clinical response after failing with subcutaneous UST treatment. No significant adverse events were observed. |
|---|